What is GYRE's market cap?

$470.79M, based on the Nov 4 close of $4.44.

Does Gyre Therapeutics pay a dividend?

No regular cash dividend has been paid in the last year.

How much of GYRE is sold short?

1.9M shares, 11.5% of float, as of Oct 15, 2026.

What sector is GYRE in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · GYREHealthcarePharmaceuticals

Gyre Therapeutics, Inc. Common Stock (GYRE)

$4.440.00%

Close Nov 4, 2026 · split-adjusted

Nov 4, 2026$4.44▼ 38.76% in range

Nov 4, 2025Low $4.44 · High $8.76Nov 4, 2026

What changed · written from our data

As of Nov 4, 2026

Gyre Therapeutics closed at $4.44 on Nov 4, unchanged, within 0.0% of its 52-week closing low. Volume of 256.2K shares was 1.65× its 20-day average (above normal).

Split-adjusted performance: -37.3% over one month, -44.8% over six months, -39.7% over one year.

In the quarter ended Jun 30, 2026, revenue was $29.11M, down 2.1% from a year earlier, with a net margin of -40.1%.

Short interest was 1.9M shares at the Oct 15 settlement (11.5% of float, 16.3 days to cover).

Market cap$470.8M106.0M shares

Revenue · quarter$29.1M−2.1% YoY

Diluted EPS$-0.12—

P/E · TTM—P/S 3.9×

Net margin-40.1%Gross 92.4%

Dividend yieldNone$0.24 last paid

52-week range4.44 – 8.76−49.3% from high

Volume256.2K1.65× 20-day avg

Volatility · 60d88.3%Annualised

Short % of float11.5%16.3 days to cover

Net cash$74.8MCash $74.8M

Next earnings—Not scheduled

Split-adjusted performance

1W −37.4%1M −37.3%3M −30.6%6M −44.8%YTD −37.1%1Y −39.7%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum29

Revenue growth38

Net margin48

Value (low P/E)—

Size60

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →

Shares short1.9M+0.5% vs prior

Days to cover16.3Settled Oct 15

% of float11.5%

Short vol. 10d66.5%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
GYREGyre Therapeutics	$4.44	0.00%	−44.8%	−2.1%	−40.1%	—	$470.8M
AQSTAquestive Therapeutics	$3.80	−2.06%	−10.2%	+38.1%	−165.5%	—	$476.9M	Compare
PHATPhathom Pharmaceuticals	$5.68	−1.05%	−55.2%	+71.1%	−16.4%	—	$461.7M	Compare
ARVNArvinas	$7.42	+4.65%	−27.7%	+1014.7%	67.8%	52.2	$485.2M	Compare
MNPRMonopar Therapeutics	$72.81	+4.18%	+14.0%	—	—	—	$488.7M	Compare
EOLSEvolus	$7.47	+1.36%	+18.2%	+21.2%	−9.6%	—	$493.4M	Compare
RLMDRelmada Therapeutics	$4.17	−2.34%	−46.9%	—	—	—	$444.8M	Compare
CRMDCorMedix	$5.66	+1.80%	−29.7%	+156.5%	25.5%	2.4	$441.2M	Compare
INDPIndaptus Therapeutics	$3.30	+1.85%	+61.0%	—	—	—	$439.7M	Compare

News about Gyre Therapeutics

All news →

Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyBenzinga · May 4, 2026▲ Positive Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire Inc. · Mar 12, 2026▲ Positive

Quick answers

What does Gyre Therapeutics do?: Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib.
What is GYRE's market cap?: $470.79M, based on the Nov 4 close of $4.44.
Does Gyre Therapeutics pay a dividend?: No regular cash dividend has been paid in the last year.
How much of GYRE is sold short?: 1.9M shares, 11.5% of float, as of Oct 15, 2026.
What sector is GYRE in?: Healthcare, in the Pharmaceuticals industry.

About Gyre Therapeutics

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

HQ: San Diego, CA618 employeesListed Oct 31, 2023gyretx.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology